Ascendis Pharma reports promising phase III data
The company has shown statistical significance for Transcon PTH as a treatment for hypoparathyroidism.
by christian bundgaard, translated by catherine brett
Ascendis Pharma has released the final phase III data from its clinical studies of candidate Transcon PTH as a treatment for hypoparathyroidism, which causes cramps and muscle spasms due to low levels of calcium and PTH.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Ascendis Pharma initiates clinical trial of dwarfism drug
For subscribers
.jpg&w=384&q=75)
